knee osteoarthritis. Bilateral primary osteoarthritis of knee
Conditions
Interventions
Intervention 1: Intervention group: L-carnitine 250 mg (made by Karen pharmaceutical and nutritional supplements manufacture), 3 tablets a day for 8 weeks. Intervention 2: Control group: placebo 3 tab
Treatment - Other
Placebo
Intervention group: L-carnitine 250 mg (made by Karen pharmaceutical and nutritional supplements manufacture), 3 tablets a day for 8 weeks
Control group: placebo 3 tablets a day for 8 weeks
Sponsors
Vice Chancellor for research of Tabriz University of Medical Sciences
Nutrition Research Center, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Female; Age: 40-60 years; Bilateral primary osteoarthritis of knee (according to ACR classification); Body mass index of 25-35; Using glucoseamine & chondrotin sulphate supplements and acetaminophene as anti-pain drug; Patient tendency and ability to participate in the study. Exclusion criteria: Severe osteoarthritis; Secondary osteoarthritis; Active synovitis; Having a history of knee injection during the past 6 months; Neurological disorder that affects movement, muscle control and balance; Uncontrolled hypertension, diabetes, cardiovascular disorders, chronic kidney disorders and functional liver disorders; Using Furosemide, Probenecid, Anticoagulants, Anticonvulsant, Sulphonamides, Methotrexate, Lithium salts and muscle relaxants; Using antioxidant supplements and w3; Smoking; History of allergy; Pregnancy and or lactation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: Before the intervention and 2 months after the intervention. Method of measurement: WOMAC questionnaire.;Joint stiffness. Timepoint: Before the intervention and 2 months after the intervention. Method of measurement: WOMAC questionnaire.;Diability. Timepoint: Before the intervention and 2 months after the intervention. Method of measurement: WOMAC questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum inflammatory factors. Timepoint: Before the intervention and 2 months after the intervention. Method of measurement: IL-1ß and hs-CRP.;Serum oxidative factors. Timepoint: Before the intervention and 2 months after the intervention. Method of measurement: Malondialdehide and total antioxidant capacity.;Serum matrix metalloproteinases. Timepoint: Before the intervention and 2 months after the intervention. Method of measurement: matrix metalloproteinase-1 and matrix metalloproteinase-13.;Nutritional status and dietary intake. Timepoint: Before the intervention and 2 months after the intervention. Method of measurement: Dietary intake: 24 hours food recall questionnaire; Nutritional status: Weight: Standard scale, Height: Stadiometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAida Malek Mahdavi
Faculty of Nutrition, Tabriz University of Medical Sciences
Outcome results
None listed